Singapore, July 22 -- The Global Antibiotic Research & Development Partnership (GARDP) and Institute of Science Tokyo, in Japan, have signed anagreement to optimise advanced compounds in GARDP's antibiotic discovery portfolio.

The organisations will look to obtain crystal structures of these compounds bound to their bacterial protein target. The findings will offer critical insights into how these compounds can be optimised into new antibiotics to treat drug-resistant bacterial infections.

The research focuses on a particular protein that is essential for the survival of Gram-negative pathogens like Escherichia coli and Klebsiella pneumoniae, both of which are WHO priority bacterial pathogens in urgent need of new treatments. This prote...